Cardiac Development: Tracing the history of a heart

Newly developed tools will help researchers understand how the human heart develops and build better models to study and treat congenital heart disease.
  1. Brian Spurlock
  2. Li Qian  Is a corresponding author
  1. Department of Pathology and Laboratory Medicine, McAllister Heart Institute, University of North Carolina, United States

In 2007, one of us lost a cousin after complications from a congenital heart defect. Doctors first realized there was a problem at the 20 week routine heart evaluation. After some initial ambiguity over the diagnosis, it became clear Wayne Preston had Hypoplastic Left Heart Syndrome (HLHS), and the left side of his heart would not be functional (Connor and Thiagarajan, 2007). Although Wayne had lost a second cousin to the same condition some 11 years earlier, the pre- and post-natal surgeries involved in treating HLHS had improved significantly since then, and doctors were cautiously optimistic. But Wayne never left the hospital. He was 19 days old when he died.

Heart defects affect almost 1 in 100 live births worldwide (van der Linde et al., 2011; Koerten et al., 2016), but studying congenital heart disease – and, more broadly, the development of the human heart – is both challenging and ethically fraught (Tan and Lewandowski, 2020). Current regulations mean that in most circumstances, in vitro cultures of human embryos can only be grown for up to two weeks. Furthermore, access to embryonic tissues that are less than six weeks post-fertilization is limited by both regulation and technical hurdles associated with collecting tissue from pregnancies terminated early (Tyser et al., 2021). Therefore, scientists largely rely on non-invasive imaging, ultrasound techniques, and useful but imperfect animal models (Hikspoors et al., 2022; de Soysa et al., 2019). Consequently, very little is known about how the human heart develops between two and five weeks post-fertilization.

The discovery in 2006 that mature differentiated cells can be reprogrammed into an embryonic-like state under certain conditions offered a revolution in the study of development (Takahashi and Yamanaka, 2006). These ‘induced pluripotent stem cells’ (iPSCs) can be programmed to become any type of cell in the body, including heart cells, offering an alternative method to study the development of the human heart in vitro. Now, in eLife, Sean Wu and colleagues – including Francisco Galdos as first author – report a new method for tracking the lineage of iPSCs as they differentiate into muscle cells of the heart (Galdos et al., 2023).

The team (who are based at Stanford University, University of California San Diego School of Medicine and Sungkyunkwan University) differentiated iPSCs into cardiac muscle cells using a common protocol involving the Wnt signaling pathway, which is crucial for normal heart development in vivo (Mandal et al., 2017; Andersen et al., 2018). Cardiac development proceeds in several stages, with the first and second heart fields arising first, shortly after gastrulation (Figure 1A). The first heart field generates the left ventricle (the part of the heart that does not develop correctly in HLHS), while the second heart field generates the right ventricle as well as the outflow tract which helps to transport blood out of the heart (Tan and Lewandowski, 2020; Zhang et al., 2021).

A new strategy for tracing the fate of iPSCs as they develop into muscle cells of the heart.

(A) Timeline (in weeks post-fertilization) of early human embryonic heart development from the blastocyst through to the emergence of the mesoderm and first (red) and second (blue) heart fields. These each give rise to different parts of the four-chambered heart: the first heart field will go on to form the primitive heart tube and left ventricle, while the second heart field cell will go on to form the right ventricle and the outflow tract. The period of development between two and five weeks post fertilization (depicted in inset) remains understudied in humans due to the 14day rule governing how long human embryos can be grown in the laboratory, as well as the low availability of fetal and embryonic tissues that are less than six weeks post-fertilization. (B) Galdos et al. developed a robust lineage tracing strategy to evaluate iPSCs that had been differentiated into cardiac cells by modulating the Wnt pathway. Under this approach, cells transitioning into first heart field cells fluoresce green, and those that terminally differentiate into ventricle muscle fluoresce red. Most cells displayed both fluorescent proteins (resulting in a yellow color), suggesting that Wnt-based differentiation predominately generates muscle cells of the left ventricle. Abbreviations: FHF – first heart field; SHF – second heart field; OFT – outflow tract; PHT – primitive heart tube; RV – right ventricle; LV – left ventricle; RA – right atrium; LA – left atrium; iPSC – induced pluripotent stem cell.

Using CRISPR/Cas9 technology, Galdos et al. developed a fluorescent reporter system which can track iPSCs that have transitioned into cells of the first heart field to eventually become muscle cells of the left ventricle. This was accomplished by adding genes for two reporter proteins. The first, a red fluorescent protein, is paired to a gene expressed in ventricular muscle cells. The second, a green fluorescent protein, is permanently turned on when an established marker of the first heart field is activated, with this activation remaining even after the marker gets deactivated later in the differentiation process (Figure 1B). Surprisingly, 95% of differentiated cells displayed both fluorescent reporters, suggesting that nearly all the iPSCs had developed into left ventricle muscle cells. Even after a more detailed examination, there was no significant trace of cells from the second heart field, suggesting that Wnt-based cardiac differentiation of iPSCs only produces muscle cells of the left ventricle.

Recent methods that can differentiate mouse and human embryonic stem cells into three-dimensional cardiac organoids have led to low but detectable proportions of second heart field cells (Pezhouman et al., 2022; Tampakakis et al., 2019). Growing iPSCs in three-dimensional cultures and organoids, rather than as a two-dimensional layer, may aid the differentiation of the second heart field by allowing cells to form structures akin to those in vivo, which could open paths to new cell fates. To test this possibility, Galdos et al. analyzed a dataset showing the genes expressed in the individual cells of cardiac organoids grown from iPSCs (Drakhlis et al., 2021). The analysis showed clusters of cells that appeared to have arisen from the second heart field, including a group that expressed a pattern of genes associated with muscle cells in the outflow tract.

Lineage tracing tools – like the one developed by Galdos et al. – can be used to see how cells respond to specific stimuli over the course of cardiac development, which will be crucial for screening drugs and testing treatments for congenital heart defects. Combining the approach created by Galdos et al. with tools that can trace the fate of other cells in the heart – such as second heart field cells, atrial muscle cells and non-muscle cells – will also allow researchers to rapidly evaluate differentiation protocols used in the laboratory and compare them to in vivo conditions. This could lead to new insights into cardiac development, such as how cells transition from one state to the next, whether some human cells proceed down previously unexplored differentiation pathways and how to direct these pathways to benefit patients. Researchers could then use these findings to generate more efficient strategies for developing heart muscle cells in the laboratory that more accurately reflect the composition of cell types found in the human heart.

Generating iPSCs from patient cells has become invaluable in understanding molecular mechanisms of disease and evaluating potential treatments. Being able to generate iPSCs from patients with HLHS, and track how these cells differentiate into cardiac muscle cells, could reveal what is causing the left ventricle to develop incorrectly. If we, as scientists, are able to achieve this goal, we may be able to prevent future mothers, fathers, sisters and cousins from losing family members to this life-threatening disease.

References

Article and author information

Author details

  1. Brian Spurlock

    Brian Spurlock is in the Department of Pathology and Laboratory Medicine, McAllister Heart Institute, University of North Carolina, Chapel Hill, United States

    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9757-4494
  2. Li Qian

    Li Qian is in the Department of Pathology and Laboratory Medicine, McAllister Heart Institute, University of North Carolina, Chapel Hill, United States

    For correspondence
    li_qian@med.unc.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7614-5618

Publication history

  1. Version of Record published:

Copyright

© 2023, Spurlock and Qian

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 967
    views
  • 74
    downloads
  • 2
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Brian Spurlock
  2. Li Qian
(2023)
Cardiac Development: Tracing the history of a heart
eLife 12:e89988.
https://doi.org/10.7554/eLife.89988

Further reading

    1. Developmental Biology
    2. Genetics and Genomics
    Anne-Sophie Pepin, Patrycja A Jazwiec ... Sarah Kimmins
    Research Article

    Paternal obesity has been implicated in adult-onset metabolic disease in offspring. However, the molecular mechanisms driving these paternal effects and the developmental processes involved remain poorly understood. One underexplored possibility is the role of paternally-induced effects on placenta development and function. To address this, we investigated paternal high-fat diet-induced obesity in relation to sperm histone H3 lysine 4 tri-methylation signatures, the placenta transcriptome and cellular composition. C57BL6/J male mice were fed either a control or high-fat diet for 10 weeks beginning at 6 weeks of age. Males were timed-mated with control-fed C57BL6/J females to generate pregnancies, followed by collection of sperm, and placentas at embryonic day (E)14.5. Chromatin immunoprecipitation targeting histone H3 lysine 4 tri-methylation (H3K4me3) followed by sequencing (ChIP-seq) was performed on sperm to define obesity-associated changes in enrichment. Paternal obesity corresponded with altered sperm H3K4me3 at promoters of genes involved in metabolism and development. Notably, sperm altered H3K4me3 was also localized at placental enhancers. Bulk RNA-sequencing on placentas revealed paternal obesity-associated sex-specific changes in expression of genes involved in hypoxic processes such as angiogenesis, nutrient transport, and imprinted genes, with a subset of deregulated genes showing changes in H3K4me3 in sperm at corresponding promoters. Paternal obesity was also linked to impaired placenta development; specifically, a deconvolution analysis revealed altered trophoblast cell lineage specification. These findings implicate paternal obesity-effects on placenta development and function as one potential developmental route to offspring metabolic disease.

    1. Developmental Biology
    2. Stem Cells and Regenerative Medicine
    Thi Thom Mac, Teddy Fauquier ... Thierry Brue
    Research Article

    Deficient Anterior pituitary with common Variable Immune Deficiency (DAVID) syndrome results from NFKB2 heterozygous mutations, causing adrenocorticotropic hormone deficiency (ACTHD) and primary hypogammaglobulinemia. While NFKB signaling plays a crucial role in the immune system, its connection to endocrine symptoms is unclear. We established a human disease model to investigate the role of NFKB2 in pituitary development by creating pituitary organoids from CRISPR/Cas9-edited human induced pluripotent stem cells (hiPSCs). Introducing homozygous TBX19K146R/K146R missense pathogenic variant in hiPSC, an allele found in congenital isolated ACTHD, led to a strong reduction of corticotrophs number in pituitary organoids. Then, we characterized the development of organoids harboring NFKB2D865G/D865G mutations found in DAVID patients. NFKB2D865G/D865G mutation acted at different levels of development with mutant organoids displaying changes in the expression of genes involved on pituitary progenitor generation (HESX1, PITX1, LHX3), hypothalamic secreted factors (BMP4, FGF8, FGF10), epithelial-to-mesenchymal transition, lineage precursors development (TBX19, POU1F1) and corticotrophs terminal differentiation (PCSK1, POMC), and showed drastic reduction in the number of corticotrophs. Our results provide strong evidence for the direct role of NFKB2 mutations in the endocrine phenotype observed in patients leading to a new classification of a NFKB2 variant of previously unknown clinical significance as pathogenic in pituitary development.